These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 3055921)

  • 1. Efficacy and long-term adverse effect pattern of lovastatin.
    Tobert JA
    Am J Cardiol; 1988 Nov; 62(15):28J-34J. PubMed ID: 3055921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMG CoA reductase inhibitors. Current clinical experience.
    Walker JF
    Drugs; 1988; 36 Suppl 3():83-6. PubMed ID: 3076126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with lovastatin.
    Tobert JA; Shear CL; Chremos AN; Mantell GE
    Am J Cardiol; 1990 Mar; 65(12):23F-26F. PubMed ID: 2180268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up.
    Bradford RH; Shear CL; Chremos AN; Dujovne CA; Franklin FA; Grillo RB; Higgins J; Langendorfer A; Nash DT; Pool JL
    Am J Cardiol; 1994 Oct; 74(7):667-73. PubMed ID: 7942524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical tolerance of lovastatin and simvastatin.
    Bilheimer DW
    Cardiology; 1990; 77 Suppl 4():58-65. PubMed ID: 2073673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.
    Bradford RH; Downton M; Chremos AN; Langendörfer A; Stinnett S; Nash DT; Mantell G; Shear CL
    Ann Intern Med; 1993 Jun; 118(11):850-5. PubMed ID: 8480959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV.
    Arch Intern Med; 1993 May; 153(9):1079-87. PubMed ID: 8481075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
    Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
    Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended clinical safety profile of lovastatin.
    Mantell G; Burke MT; Staggers J
    Am J Cardiol; 1990 Sep; 66(8):11B-15B. PubMed ID: 2206031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators.
    Simons LA
    Clin Cardiol; 1993 Apr; 16(4):317-22. PubMed ID: 8458112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin.
    Dujovne CA; Chremos AN; Pool JL; Schnaper H; Bradford RH; Shear CL; Higgins J; Downton M; Franklin FA; Nash DT
    Am J Med; 1991 Jul; 91(1B):25S-30S. PubMed ID: 1831006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III.
    JAMA; 1988 Jul; 260(3):359-66. PubMed ID: 2898027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lovastatin: a new cholesterol-lowering agent.
    McKenney JM
    Clin Pharm; 1988 Jan; 7(1):21-36. PubMed ID: 3278832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of statins: effects on muscle and the liver.
    Vasudevan AR; Hamirani YS; Jones PH
    Cleve Clin J Med; 2005 Nov; 72(11):990-3, 996-1001. PubMed ID: 16315438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR; Tobert JA
    Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic use of lovastatin in the treatment of hypercholesterolemia.
    Illingworth DR
    Clin Ther; 1994; 16(1):2-26; discussion 1. PubMed ID: 8205598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.